bkp_duke
Well-Known Member
When the authorized and studied regimen for EACH of these vaccines is two doses, giving one of each is giving two half doses. You dispute that?
Or, when you say two full doses, are you advocating double doses for each vaccine, respectively? Are there studies that show that doing such will actually reduce the spread? Because that seems to take 50% of available vaccine off the table at a time of shortage. I'm trying to understand your logic.
Typical laywer, semantics (I joke, don't come sue me).
The EUA for Moderna is two shots, 100 ug (micrograms) each.
The EUA for Pfizer is two shots, 30 ug (micrograms) each.
Substitute those in for what I said above.
NOW, with that said, we have GOOD data in a recent study (actually data was out before this, but you had to dig) that shows a SINGLE shot of Moderna (100 ug) or Pfizer (30 ug) confers 80% protection. ADDITIONALLY, Moderna in their trial also tested a 50 ug shot dose, and very clearly showed an almost identical antibody response after the first dose, and again after the 2nd dose, to the "full strength" 100 ug dosing regimen. A third, 25 ug dose, was also tested but did not elicit the same level of Antibody production as the 50 and 100 ug doses.
As frequent readers of this thread will remember, I pointed out month ago, that the FASTEST way to get us to herd immunity was to cut the Moderna dose in half (i.e. 50 ug) and get as many shots in as many arms as possible. NOT administering the second dose until after the bulk of the population, or at least the high-risk groups, had that first dose. This was a VERY talked about option at the end of December, with Fauci, etc. mentioning the merits of such, but unwilling to put their weight behind the idea because that is not exactly how the clinical trials were run.
Hopefully that clarifies my medical opinion, as a physician and a molecular biologist, of how I would have run the vaccine roll-out. This would have only applied to the Moderna vaccine, because Pfizer did not do the same dosing comparisons in their Phase 2/3 trials.